ArticleInternational journal of cancer2017

Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.

Konrad Klinghammer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.